For COVID-19 and vaccination updates, view our information for the community. If you're experiencing symptoms, call your primary care provider.
Comparing The Outcome Of Immunotherapy-Based Drug Combination Therapy With Or Without Surgery To Remove The Kidney In Metastatic Kidney Cancer
To compare Standard Systemic Therapy alone to Standard Systemic Therapy plus surgery to remove all or part of the kidney with tumor.
DiagnosisPatients who have kidney cancer that has spread outside of their kidney.
Participants must have a histologically proven diagnosis of clear cell or non-clear cell renal cell carcinoma.
Participants with collecting duct carcinoma histology are not eligible.
Participants with multifocal or bilateral tumors are eligible
Patients must sign an approved informed consent and authorization permitting release of personal health information.
This study has 2 study groups:
- Group 1: Patients in this group will continue to receive standard systemic therapy until their disease gets worse or the side effects are too great.
- Group 2: Patients in this group will continue to receive standard systemic therapy, but patients will also have surgery to remove part or all of your kidney.
For more information, visit ClinicalTrials.gov